RMTI Rockwell Medical

Court Denies Rockwell’s Motion for Preliminary Injunction against Richmond Brothers and Mark H. Ravich

Richmond Brothers, Inc., a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell” or the “Company”), and Mark H. Ravich, who together with their affiliates beneficially own nearly 6.1 million shares, or 11.7% of the Company’s outstanding common stock, today announced that the U.S. District Court for the Eastern District of Michigan, Southern Division, has issued an order denying Rockwell’s motion for preliminary injunction against Richmond Brothers and Mark H. Ravich.

Rockwell had sought this preliminary injunction in order to require Richmond / Ravich to amend their Schedule 13D filing and prohibit them from soliciting shareholder votes in the context of their proxy contest to elect Mark H. Ravich to the Board.

David S. Richmond, Chairman of Richmond Brothers, Inc., and Mark H. Ravich said, “After Rockwell has repeatedly referenced the claims in this lawsuit to dissuade shareholders from supporting us, we are pleased to share the Court’s ruling with the Rockwell investment community. The ruling makes clear that shareholders will be afforded a full opportunity to cast their votes as they deem appropriate. We will continue to make our case for change at Rockwell as we approach the Company’s annual meeting.”

Shareholders who have already voted on the BLUE proxy card to elect Mark H. Ravich to the Board need take no further action. Shareholders who have voted on the Company’s white proxy card may change their vote by voting a later-dated BLUE proxy card today. Voting withhold on Rockwell’s nominee on the white proxy card is not the same as voting for Mark H. Ravich on the BLUE proxy card.

For more information, and to see other communications and filings from Richmond Brothers and Mark H. Ravich, visit this link: http://www.richmondbrothers.com/time-for-action-at-rmti.

VOTE THE BLUE PROXY CARD TO ELECT MARK H. RAVICH TODAY

You may vote by internet or telephone by following the instructions on the form you have been provided.

If you have any questions, or require assistance with your vote, please contact Saratoga Proxy

Consulting LLC, toll- free at (888) 368-0379, call direct at (212) 257-1311 or email:

[email protected]

About Richmond Brothers, Inc.

Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994.

About Mark H. Ravich

Mark H. Ravich is a private investor and currently serves as President of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998.

EN
25/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rockwell Medical

 PRESS RELEASE

Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...

 PRESS RELEASE

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...

 PRESS RELEASE

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch